Top

Published in:

01-09-2011 | Original Article

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases

Authors: Catarina Eloy, Joana Santos, Paula Soares, Manuel Sobrinho-Simões

Published in: Virchows Archiv | Issue 3/2011

Abstract

Prognostic factors indicative of papillary thyroid carcinoma (PTC) aggressive behaviour remain incompletely established partially due to the different composition of the series on record regarding the relative proportion of classic PTC (CPTC) and follicular variant PTC (FVPTC) subtypes. Several clinico-morphological features of PTC, together with the occurrence of BRAF mutations, are still not fully accepted as markers of aggressiveness. In the present clinico-pathological study of a series of 75 CPTC and FVPTC cases, we evaluated the relative contribution of the morphological features of the tumours and their BRAF and N-RAS status for the occurrence of nodal metastases. The morphological features most closely related to the occurrence of nodal metastases were extra-thyroid extension and poorly circumscribed growth pattern, in both CPTC and FVPTC. Additional features significantly associated to nodal metastases were multicentricity in the CPTC and vascular invasion in the FVPTC group. BRAF V600E mutation was detected in 29% of tumours, 41% of CPTC and 16% of FVPTC; N-RAS Q61R mutation was detected in 6% of tumours, 3% of CPTC and 10% of FVPTC. BRAF mutation was significantly more frequent in the CPTC group and in females, and it was detected only in patients older than 20 years, suggesting a late tumourigenic effect in the development of PTC. BRAF mutation was not significantly associated to any of the other studied features related to aggressiveness or nodal metastases. These results highlight the importance of infiltrative growth pattern and invasiveness over the presence of BRAF mutation in classic and follicular variant PTC for the development of nodal metastases.

DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumors of endocrine organs. IARC, Lyon

Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P (2005) Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447:787–793PubMedCrossRef

Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle RM, Fagin JA, Ghossein RA (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200PubMedCrossRef

Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C (2006) Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-RAS mutation in codon 61 with follicular variant. Hum Pathol 37:824–830PubMedCrossRef

Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA (2006) Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107:1255–1264PubMedCrossRef

Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J (1985) Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805–828PubMedCrossRef

Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer 79:564–573PubMedCrossRef

Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J (2010) Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34:868–872PubMedCrossRef

Sobrinho-Simões M, Eloy C, Vinagre J, Soares P (2010) Molecular pathology of thyroid tumors: diagnostic and prognostic relevance. Int J Surg Pathol 18:209S–212SPubMedCrossRef

10.

van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, Grant CS (1992) Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112:1130–1136PubMed

11.

Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C (1985) Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794–804PubMedCrossRef

12.

Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943–3949PubMedCrossRef

13.

Rosai J, LiVolsi VA, Sobrinho-Simões M, Williams ED (2003) Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. Int J Surg Pathol 11:249–251PubMedCrossRef

14.

Niemeier LA, Kuffner HA, Carty S, Stewart AF, Nikiforov YE (2010) A combined molecular-pathological score to predict aggressiveness of thyroid papillary microcarcinoma. Mod Pathol. Abst 578, p. 131A

15.

Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95:4197–4205PubMedCrossRef

16.

Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589–595PubMedCrossRef

17.

Trovisco V, Couto JP, Cameselle-Teijeiro J, de Castro IV, Fonseca E, Soares P, Sobrinho-Simões M (2008) Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 69:683–685CrossRef

18.

Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578–4580PubMedCrossRef

19.

Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818–821PubMed

20.

Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–4397PubMedCrossRef

21.

Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F (2004) BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414–2420PubMedCrossRef

22.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561–4567PubMed

23.

Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef

24.

Trovisco V, Soares P, Preto A, Castro P, Máximo V, Sobrinho-Simões M (2007) Molecular genetics of papillary thyroid carcinoma—great expectations… Arq Bras. Endocrinol Metab 51:643–653

25.

Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89–97PubMedCrossRef

26.

Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, Vieira de Castro I, Cardoso de Oliveira M, Fonseca E, Soares P, Sobrinho-Simões M (2006) PAX8-PPARg rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–220PubMedCrossRef

27.

Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE (2003) Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusual high prevalence of RAS mutations. Am J Clin Pathol 120:71–77PubMedCrossRef

28.

Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD, Jameson JL (1991) RAS oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832–836PubMedCrossRef

29.

Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR (1991) High rates of RAS codon 61 mutation in thyroid tumors in an iodine deficient area. Cancer Res 51:2690–2693PubMed

30.

Xing M, Clarck D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977–2982PubMedCrossRef

31.

Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J, Ghossein R (2010) Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 20:1085–1093PubMedCrossRef

32.

Sobrinho-Simões M, Eloy C, Lobo C, Magalhães J, Amaro T (2011) Follicular thyroid carcinoma. Mod Pathol 24:S10–S18PubMedCrossRef

33.

Widder S, Guggisberg K, Khalil M, Pasieka JL (2008) A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery 144:80–85PubMedCrossRef

34.

Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, Greco A, Astakahova L, Butti MG, Demidchik EP, Pacini F, Pierotti MA (1995) Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to Chernobyl nuclear accident. Cancer Res 55:5617–5620PubMed

35.

Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690–1694PubMed

36.

Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G (2006) RET/Papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91:2414–23PubMedCrossRef

37.

Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D (2004) BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365–8PubMedCrossRef

38.

Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294–303PubMedCrossRef

39.

Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544–52PubMedCrossRef

40.

Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene. doi:10.1038/onc.2011.44

41.

Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA (2011) Thyrotrophin receptor signaling dependence of BRAF-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108:1615–1620PubMedCrossRef

42.

Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357–3364PubMedCrossRef

43.

Soares P, Sobrinho-Simões M (2009) Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer? Future Oncol 5:1225–1229PubMedCrossRef

44.

Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS (2011) Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 96:658–664PubMedCrossRef

45.

Tang KT, Lee CH (2010) BRAF mutation in papillary thyroid carcinoma: pathologic role and clinical implications. J Chin Med Assoc 73:113–128PubMedCrossRef

46.

Melck AL, Yip L, Carty SE (2010) The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist 15:1285–1293PubMedCrossRef

47.

Soares P, Sobrinho-Simões M (2011) Small papillary thyroid cancers—is BRAF of prognostic value? Nat Rev Endocrinol 7:9–10PubMedCrossRef

48.

Couto JP, Prazeres H, Castro P, Lima J, Máximo V, Soares P, Sobrinho-Simões M (2009) How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer? J Clin Pathol 62:414–421PubMedCrossRef

49.

Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714–4719PubMedCrossRef

50.

Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y (2003) Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237:399–407PubMed

51.

Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA (2005) Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65:2465–2473PubMedCrossRef

52.

Castro P, Fonseca E, Magalhaes J, Sobrinho-Simoes M (2002) Follicular, papillary, and "hybrid" carcinomas of the thyroid. Endocr Pathol 13:313–320PubMedCrossRef

Title: The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases
Authors: Catarina Eloy
Joana Santos
Paula Soares
Manuel Sobrinho-Simões
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 3/2011
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-011-1133-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma

Matrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistance

Alterations of ubiquitylation and sumoylation in conventional renal cell carcinomas after the Chernobyl accident: a comparison with Spanish cases

The incidence of lymphocytic thyroid infiltration and Hashimoto's thyroiditis increased in patients operated for benign goiter over a 31-year period

What skeletons tell us. The story of human paleopathology

Lysozyme-rich mucus metaplasia in duodenal crypts supersedes Paneth cells in celiac disease